
        <html>
        <head><title>CRCL 8-K Filing</title></head>
        <body>
        <h1>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</h1>
        <h2>FORM 8-K</h2>
        <h3>CURRENT REPORT</h3>
        
        <p><b>Company:</b> Cericor Inc. (CRCL)</p>
        <p><b>Date:</b> December 15, 2024</p>
        
        <h3>Item 1.01 Entry into a Material Definitive Agreement</h3>
        <p>On December 15, 2024, Cericor Inc. entered into a merger agreement with 
        Voyager Acquisition Corp. The transaction values CRCL at approximately $450 million.</p>
        
        <h3>Item 2.02 Results of Operations and Financial Condition</h3>
        <p>CRCL reported Q3 2024 revenues of $87.5 million, up 23% year-over-year. 
        The company's diagnostic platform processed over 150,000 tests during the quarter.</p>
        
        <h3>Item 7.01 Regulation FD Disclosure</h3>
        <p>Key highlights from the quarter include:
        - Launch of new AI-powered diagnostic tools
        - Expansion into three new metropolitan markets
        - Partnership with major hospital network
        - FDA clearance for two new diagnostic tests</p>
        
        <h3>Risk Factors</h3>
        <p>The company faces risks including regulatory changes, competition from larger 
        diagnostic companies, and dependence on key supplier relationships.</p>
        </body>
        </html>
        